E-LIB Suche - Ergebnisse für: Nangia, Narinder

1

Combination of olanzapine and samidorphan has no clinically..:

Sun, Lei ; Yagoda, Sergey ; Xue, Hongqi...
Progress in Neuro-Psychopharmacology and Biological Psychiatry. 100 (2020) - p. 109881 , 2020

Link: https://doi.org/10.1016/..

2

143 A Combination of Olanzapine and Samidorphan Has No Clin..:

Sun, Lei ; Yagoda, Sergey ; Xue, Hongqi...
CNS Spectrums. 25 (2020) 2 - p. 291-291 , 2020

Link: https://doi.org/10.1017/..

3

Transition of Patients with Opioid Use Disorder from Bupren..:

Comer, Sandra D. ; Mannelli, Paolo ; Alam, Danesh...
The American Journal on Addictions. 29 (2020) 4 - p. 313-322 , 2020

Link: https://doi.org/10.1111/..

4

Reply to Kunoe (2020) and Ghosh & Singh (2020) regarding Nu..:

Nunes, Edward V. ; Bisaga, Adam ; Krupitsky, Evgeny...
Addiction. 115 (2020) 11 - p. 2188-2190 , 2020

Link: https://doi.org/10.1111/..

5

Cognitive performance of patients with opioid use disorder ..:

Kosten, Thomas ; Aharonovich, Efrat ; Nangia, Narinder...
Addictive Behaviors. 111 (2020) - p. 106538 , 2020

Link: https://doi.org/10.1016/..

6

Diroximel fumarate (DRF) in patients with relapsing–remitti..:

Naismith, Robert T ; Wolinsky, Jerry S ; Wundes, Annette...
Multiple Sclerosis Journal. 26 (2019) 13 - p. 1729-1739 , 2019

Link: https://doi.org/10.1177/..

7

5 Clinical Evaluation of the Abuse Potential of Buprenorphi..:

Cutler, Andrew J. ; Mathew, Sanjay J. ; DeBakey, Michael E....
CNS Spectrums. 24 (2019) 1 - p. 176-176 , 2019

Link: https://doi.org/10.1017/..

8

Opioid use and dropout from extended‐release naltrexone in ..:

Nunes, Edward V. ; Bisaga, Adam ; Krupitsky, Evgeny...
Addiction. 115 (2019) 2 - p. 239-246 , 2019

Link: https://doi.org/10.1111/..

9

Abuse Potential of Samidorphan: A Phase I, Oxycodone‐, Pent..:

Pathak, Sanjeev ; Vince, Bradley ; Kelsh, Debra...
The Journal of Clinical Pharmacology. 59 (2018) 2 - p. 218-228 , 2018

Link: https://doi.org/10.1002/..

10

Outpatient transition to extended-release injectable naltre..:

Bisaga, Adam ; Mannelli, Paolo ; Yu, Miao...
Drug and Alcohol Dependence. 187 (2018) - p. 171-178 , 2018

Link: https://doi.org/10.1016/..

11

S99. Evaluation of Abuse Potential of Samidorphan in Health..:

Setnik, Beatrice ; Nangia, Narinder ; Puhl, Matthew D....
Biological Psychiatry. 83 (2018) 9 - p. S385 , 2018

Link: https://doi.org/10.1016/..

12

Opioid system modulation with buprenorphine/samidorphan com..:

Fava, Maurizio ; Thase, Michael E. ; Trivedi, Madhukar H....
Molecular Psychiatry. 25 (2018) 7 - p. 1580-1591 , 2018

Link: https://doi.org/10.1038/..

13

Abuse Potential of Buprenorphine/Samidorphan Combination Co..:

Pathak, Sanjeev ; Vince, Bradley ; Kelsh, Debra...
The Journal of Clinical Pharmacology. 59 (2018) 2 - p. 206-217 , 2018

Link: https://doi.org/10.1002/..

14

F172. Clinical Evaluation of Abuse Potential of ALKS 5461:

Setnik, Beatrice ; Mathew, Sanjay J. ; Setnik, Beatrice...
Biological Psychiatry. 83 (2018) 9 - p. S305 , 2018

Link: https://doi.org/10.1016/..

15

EVOLVE-MS-1: A Phase 3, Open-Label, Long-Term Safety Study ..:

Naismith, Robert ; Leigh-Pemberton, Richard ; Rezendes, David...
Neurology. 90 (2018) 15_supplement - p. , 2018

Link: https://doi.org/10.1212/..